Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesKyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.805 USD -0.32 ( 6.15%)
Last update at 2026-11-12T15:26:00Z
VOLUME
302283
Market Cap
0.00M

Momentum Score

…

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.77
Low
5.32
High
52 Week Price Range
12.15
Low
35.06
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Publicly available information on Kyverna Therapeutics is limited; prospective investors should consult the company’s SEC filings and press releases for program-level details. From disclosures, the company operates in the biotech/biopharma sector and long-term growth drivers likely include advancement of clinical-stage programs, regulatory milestones, and strategic partnerships, which may benefit long-term value if development progress is achieved.
Key investment risks include clinical and regulatory failure, the need for additional capital leading to dilution, and the commercial and execution risks typical of small-cap biotechnology companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
5.12
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
-
ROCE
-112.78%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Income before tax -60.37M -28.89M -26.35M
Net income -60.37M -28.89M -26.35M
Selling general administrative 12.48M 8.01M 6.15M
Reconciled depreciation 1.71M 1.05M 0.59M
Operating income -62.41M -29.38M -26.35M
Interest expense 0.19M 0.07M 0.00M
Interest income 2.28M 0.56M 0.00M
Net interest income 2.10M 0.50M -0.00M
Total revenue 0.00M 7.03M 5.66M
Total operating expenses 62.41M 36.41M 32.00M
Total other income expense net -0.06M -0.01M -0.00M
Net income from continuing ops -60.37M -28.89M -26.35M
Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Total assets 75.19M 66.92M 85.49M
Other current assets 3.12M 1.93M 1.02M
Total liab 206.59M 140.92M 131.74M
Total stockholder equity -131.40M -74.00M -46.25M
Other current liab 3.52M 0.56M 0.57M
Capital stock 0.00M 0.00M 0.00M
Retained earnings -136.04M -75.68M -46.78M
Cash 34.65M 37.73M 76.07M
Total current liabilities 19.86M 11.95M 15.93M
Total current assets 60.66M 53.25M 77.09M
Short term investments 22.90M 13.59M 0.00M
Accounts payable 4.36M 1.45M 0.77M
Non currrent assets other 3.92M 1.23M 0.59M
Non current assets total 14.53M 13.67M 8.40M
Capital lease obligations 9.08M 10.56M 5.55M
Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Investments -8.79M -14.10M -1.29M
Total cash from financing activities 58.12M 11.88M 72.52M
Net income -60.37M -28.89M -26.35M
Change in cash -3.08M -38.33M 49.08M
Begin period cash flow 38.29M 76.62M 27.54M
End period cash flow 35.21M 38.29M 76.62M
Total cash from operating activities -52.41M -36.11M -22.16M
Issuance of capital stock 59.90M 11.95M 72.53M
Depreciation 1.71M 1.05M 0.59M
Capital expenditures 0.62M 0.77M 1.29M
Change in working capital 3.42M -10.33M -4.49M
Stock based compensation 2.22M 0.93M 7.25M
Other non cash items 1.72M 1.41M 0.83M
Free cash flow -53.03M -36.88M -23.44M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
KYTX
Kyverna Therapeutics, Inc. Common Stock		 -0.32
6.15%		 4.80 - - - -
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

5980 Horton Street, Emeryville, CA, United States, 94608

(510) 925-2492

https://kyvernatx.com

96

Name Title Year Born
Dr. Peter Maag Ph.D. CEO & Director 1967
Ms. Karen Walker Chief Technology Officer 1962
Dr. James Chung M.D., Ph.D. Chief Medical Officer 1968
Mr. Ryan Jones Chief Financial Officer 1988
Dr. Tom Van Blarcom Ph.D. Senior VP & Head of Research NA
Ms. Portia Serame Vice President of Human Resources NA
Dr. Dominic Borie M.D., Ph.D. President of Research & Development 1963
Mr. Devin Murray Senior Vice President of Partnerships & Alliances NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…